中恆集團(600252.SH):萊美藥業擬轉讓禾正製藥100%股權
格隆匯3月11日丨中恆集團(600252.SH)公佈,公司控股子公司萊美藥業將持有禾正製藥100%股權(含其全資子公司成都禾正生物科技有限公司(以下簡稱“成都禾正”)、四川萊禾醫藥科技有限公司(以下簡稱“萊禾科技”))以人民幣1.65億元轉讓給杭州布萊森醫藥科技有限公司(以下簡稱“布萊森”)。
本次股權轉讓交易事項完成後,禾正製藥(含成都禾正和萊禾科技)將不再納入萊美藥業合併報表範圍。本次股權轉讓交易事項預計對萊美藥業產生收益約為人民幣2853萬元。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.